582
Participants
Start Date
July 7, 2022
Primary Completion Date
October 20, 2023
Study Completion Date
October 20, 2023
Insulin glargine/Lixisenatide
solution, by subcutaneous injection
IDegAsp
solution, by subcutaneous injection
Metformin
Tablet, orally
SGLT2 inhibitor
Tablet, orally
Investigational Site Number : 1560001, Beijing
Investigational Site Number : 1560027, Beijing
Investigational Site Number : 1560009, Shenyang
Investigational Site Number : 1560053, Dalian
Investigational Site Number : 1560047, Tonghua
Investigational Site Number : 1560059, Changchun
Investigational Site Number : 1560046, Changchun
Investigational Site Number : 1560045, Harbin
Investigational Site Number : 1560003, Shanghai
Investigational Site Number : 1560020, Shanghai
Investigational Site Number : 1560007, Shanghai
Investigational Site Number : 1560028, Nanjing
Investigational Site Number : 1560034, Zhenjiang
Investigational Site Number : 1560060, Lianyungang
Investigational Site Number : 1560056, Huai'an
Investigational Site Number : 1560057, Nantong
Investigational Site Number : 1560040, Jinan
Investigational Site Number : 1560014, Jinan
Investigational Site Number : 1560048, Qingdao
Investigational Site Number : 1560016, Tianjin
Investigational Site Number : 1560013, Tianjin
Investigational Site Number : 1560010, Hangzhou
Investigational Site Number : 1560037, Pingxiang
Investigational Site Number : 1560044, Chongqing
Investigational Site Number : 1560011, Changsha
Investigational Site Number : 1560005, Zhuzhou
Investigational Site Number : 1560033, Yueyang
Investigational Site Number : 1560052, Changde
Investigational Site Number : 1560058, Jingzhou
Investigational Site Number : 1560055, Huangshi
Investigational Site Number : 1560035, Huanggang
Investigational Site Number : 1560031, Luoyang
Investigational Site Number : 1560043, Guangzhou
Investigational Site Number : 1560029, Guangzhou
Investigational Site Number : 1560022, Huizhou
Investigational Site Number : 1560030, Foshan
Investigational Site Number : 1560054, Chengdu
Investigational Site Number : 1560024, Chengdu
Investigational Site Number : 1560002, Zigong
Investigational Site Number : 1560039, Lanzhou
Investigational Site Number : 1560008, Baotou
Investigational Site Number : 1560019, Beijing
Investigational Site Number : 1560004, Chenzhou
Investigational Site Number : 1560025, Harbin
Investigational Site Number : 1560038, Hohhot
Investigational Site Number : 1560051, Huzhou
Investigational Site Number : 1560041, Kaifeng
Investigational Site Number : 1560017, Nanjing
Investigational Site Number : 1560018, Nanjing
Investigational Site Number : 1560012, Qinhuangdao
Investigational Site Number : 1560006, Shanghai
Investigational Site Number : 1560050, Suzhou
Investigational Site Number : 1560015, Xuzhou
Investigational Site Number : 1560032, Yueyang
Investigational Site Number : 1560049, Zhengzhou
Investigational Site Number : 1560036, Zhongshan
Investigational Site Number : 1560023, Cangzhou
Investigational Site Number : 1560021, Handan
Investigational Site Number : 1560042, Xingtai
Investigational Site Number : 1560026, Yuncheng
Lead Sponsor
Sanofi
INDUSTRY